Journal Article

FZJ-2024-06250

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Elevated Aβ aggregates in feces from Alzheimer’s disease patients: a proof-of-concept study

Pils, M. (First author)FZJ* ; Dybala, A. ; Schaffrath, A. ; Rehn, F.FZJ* ; Kutzsche, J.FZJ* ; Blömeke, L.FZJ* ; Tusche, M.FZJ* ; Özdüzenciler, P.FZJ* ; Bujnicki, T.FZJ* ; Kraemer-Schulien, V.FZJ* ; Gramespacher, H. ; Schmieschek, M. H. T. ; Barbe, M. T. ; Onur, O. A. ; Fink, G. R.FZJ* ; Tamgüney, G.FZJ* ; Bannach, O.FZJ* ; Willbold, D. (Corresponding author)FZJ*

2024
BioMed Central London

This record in other databases:      

Please use a persistent id in citations: doi:10.1186/s13195-024-01597-3  doi:10.34734/FZJ-2024-06250

Abstract: BackgroundMisfolding and aggregation of amyloid β (Aβ), along with neurofibrillary tangles consisting of aggregated Tau species, are pathological hallmarks of Alzheimer’s disease (AD) onset and progression. In this study, we hypothesized the clearance of Aβ aggregates from the brain and body into the gut.MethodsTo investigate this, we used surface-based fluorescence intensity distribution analysis (sFIDA) to determine the Aβ aggregate concentrations in feces from 26 AD patients and 31 healthy controls (HC).ResultsAβ aggregates were detectable in human feces and their concentrations were elevated in AD patients compared to HC (specificity 90.3%, sensitivity 53.8%).ConclusionThus, fecal Aβ aggregates constitute a non-invasive biomarker candidate for diagnosing AD. Whether digestion-resistant Aβ aggregates in feces are secreted via the liver and bile or directly from the enteric neuronal system remains to be elucidated.

Note: sFIDA was supported by the programs “Biomarkers Across Neurodegenerative Diseases I + II” of The Alzheimer’s Association, Alzheimer’s Research UK, and the Weston Brain Institute [11084, BAND-19-614337]. We are also grateful for support from The Michael J. Fox Foundation for Parkinson’s Research [14977, 009889], the ALS Association, and the Packard Center [19-SI-476]. We received further funding from the Deutsche Forschungsgemeinschaft [INST 208/616-1 FUGG, INST 208/794-1 FUGG], Helmholtz Association [HVF0079], Förderstiftung Dierichs, and Deutsche Alzheimer Gesellschaft e.V. Selbsthilfe Demenz (DalzG). G.R.F. and O.A.O. were supported by the Marga and Walter Boll-Foundation. H.G. was supported by the Cologne Clinician Scientist Program (CCSP) / Faculty of Medicine / University of Cologne and received funding from Deutsche Forschungsgemeinschaft [DFG, FI 773/15 − 1].Open Access funding enabled and organized by Projekt DEAL.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)
2. Strukturbiochemie (IBI-7)

Research Program(s):

1. 5251 - Multilevel Brain Organization and Variability (POF4-525) (POF4-525)
2. 5244 - Information Processing in Neuronal Networks (POF4-524) (POF4-524)

Appears in the scientific report 2024

---

Database coverage:
; ; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---